CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Despite remarkable success in the treatment of hematological malignancies, CAR T-cell therapies for solid tumors have floundered, in large part due to local immune suppression and the effects of prolonged stimulation leading to T-cell dysfunction and exhaustion. One mechanism by which gliomas and ot...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Bryan D., Yu, Xiaoling, Castano, Ana P., Darr, Henia, Henderson, Daniel B., Bouffard, Amanda A., Larson, Rebecca C., Scarfò, Irene, Bailey, Stefanie R., Gerhard, Genevieve M., Frigault, Matthew J., Leick, Mark B., Schmidts, Andrea, Sagert, Jason G., Curry, William T., Carter, Bob S., Maus, Marcela V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857271/
https://www.ncbi.nlm.nih.gov/pubmed/31727131
http://dx.doi.org/10.1186/s40425-019-0806-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857271/
https://www.ncbi.nlm.nih.gov/pubmed/31727131
http://dx.doi.org/10.1186/s40425-019-0806-7

Ejemplares similares